BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 28138878)

  • 1. Preoperative platelet-lymphocyte ratio is an independent prognostic marker and superior to carcinoembryonic antigen in colorectal peritoneal carcinomatosis patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Bong TSH; Tan GHC; Chia C; Soo KC; Teo MCC
    Int J Clin Oncol; 2017 Jun; 22(3):511-518. PubMed ID: 28138878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer: The prognostic impact of baseline neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios.
    Zager Y; Hoffman A; Dreznik Y; Jacoby H; Cordoba M; Horesh N; Nevler A; Gutman M; Berger Y
    Surg Oncol; 2020 Dec; 35():321-327. PubMed ID: 32977104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.
    Lee L; Alie-Cusson F; Dubé P; Sideris L
    J Surg Oncol; 2017 Aug; 116(2):236-243. PubMed ID: 28409831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative neutrophil-to-lymphocyte ratio and plateletto- lymphocyte ratio as new prognostic factors for patients with colorectal cancer.
    Mahsuni Sevinc M; Riza Gunduz U; Kinaci E; Armagan Aydin A; Bayrak S; Umar Gursu R; Gunduz S
    J BUON; 2016; 21(5):1153-1157. PubMed ID: 27837617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study.
    Cashin PH; Graf W; Nygren P; Mahteme H
    Eur J Surg Oncol; 2012 Jun; 38(6):509-15. PubMed ID: 22475555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
    Kozman MA; Fisher OM; Rebolledo BJ; Parikh R; Valle SJ; Arrowaili A; Alzahrani N; Liauw W; Morris DL
    J Surg Oncol; 2018 Mar; 117(4):725-736. PubMed ID: 29266235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
    Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
    Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival prognostic factors in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy: a single institution experience.
    Nikolic S; Dzodic R; Zegarac M; Djurisic I; Gavrilovic D; Vojinovic V; Kocic M; Santrac N; Radlovic P; Radosavljevic D; Pupic G; Martinovic A
    J BUON; 2014; 19(1):66-74. PubMed ID: 24659645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
    Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
    World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center.
    Teo MC; Ching Tan GH; Lim C; Chia CS; Tham CK; Soo KC
    Asian J Surg; 2015 Apr; 38(2):65-73. PubMed ID: 25059814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of aggressive histology and location of primary tumor on the efficacy of surgical therapy for peritoneal carcinomatosis of colorectal origin.
    Winer J; Zenati M; Ramalingam L; Jones H; Zureikat A; Holtzman M; Lee K; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2014 May; 21(5):1456-62. PubMed ID: 24201745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel prognostic score for outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with metachronous peritoneal carcinomatosis.
    Chin KM; Tan GHC; Chia CS; Ong JCA; Teo MCC
    ANZ J Surg; 2020 Oct; 90(10):1958-1964. PubMed ID: 32159299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
    van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
    Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center.
    Wu HT; Peng KW; Ji ZH; Sun JH; Zhang Q; Yang XJ; Huang CQ; Li Y
    Eur J Surg Oncol; 2016 Jul; 42(7):1024-34. PubMed ID: 27179924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curative cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis and synchronous resectable liver metastases arising from colorectal cancer.
    Lorimier G; Linot B; Paillocher N; Dupoiron D; Verrièle V; Wernert R; Hamy A; Capitain O
    Eur J Surg Oncol; 2017 Jan; 43(1):150-158. PubMed ID: 27839895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
    Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
    Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative neutrophil-lymphocyte ratio before platelet-lymphocyte ratio predicts clinical outcome in patients with cervical cancer treated with initial radical surgery.
    Zhang Y; Wang L; Liu Y; Wang S; Shang P; Gao Y; Chen X
    Int J Gynecol Cancer; 2014 Sep; 24(7):1319-25. PubMed ID: 25033256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Relevance of the Peritoneal Surface Disease Severity Score Compared to the Peritoneal Cancer Index for Colorectal Peritoneal Carcinomatosis.
    Ng JL; Ong WS; Chia CS; Tan GH; Soo KC; Teo MC
    Int J Surg Oncol; 2016; 2016():2495131. PubMed ID: 27006828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of preoperative neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in patients with gallbladder carcinoma.
    Zhang Y; Jiang C; Li J; Sun J; Qu X
    Clin Transl Oncol; 2015 Oct; 17(10):810-8. PubMed ID: 26077119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.